Video

David Gershenson on Challenges to Advancing Treatment for Rare Ovarian Cancers

Author(s):

David Gershenson, M.D.
Conference|Ovarian Cancer National Conference

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors.

David Gershenson, M.D., of MD Anderson Cancer Center, explains the difficulty of advancing treatment of rare ovarian cancers: malignant ovarian germ cell tumors, sex cord stromal tumors, and types of epithelial tumors such as ovarian clear cell carcinoma, ovarian low-grade serous carcinoma, and mucinous tumors. With such a low number of cases and not much interest from pharmaceutical companies, it is hard to conduct clinical trials in these areas.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of two doctors and text.
Imiage of two doctors with text.
Image of two doctors and text.
Image of patient and doctor.
Image of two doctors with text.
image of gerds
Image of 2 doctors and text.
Image of two doctors and text.
Image of thumbnail.
Image of doctor.
Related Content
Image of two doctors with text.
June 22nd 2025

Experts Impart Notable Information and Updates for Those With Blood Cancers

Dr. Joshua K. Sabari Dr. Nausheen Ahmed
The 2025 ASCO Annual Meeting brought many different updates to light in the realm of hematological malignancies, including multiple myeloma and lymphoma.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Image of breast.
June 19th 2025

Breaking Down the Impact of SERENA-6 for Some With Breast Cancer

Ryan Scott
Dr. Joshua K. Sabari and Dr. Julia E. McGuinness discussed the SERENA-6 trial and its outcomes for patients with ESR1-mutated HR+/HER2— breast cancer.
cancer horizons image for podcast
December 14th 2023

Conference Highlights from the 2023 ASH Annual Meeting

Brielle Benyon Alex Biese
CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.
Image of hands.
June 18th 2025

The Person Behind Their Diagnosis: Understanding the Patient

Ryan Scott
Dr. Joshua Sabari and Jackie Herigodt discuss the Imerman Angels organization and the importance of recognizing the person behind their cancer diagnosis.
image of lung scan.
June 16th 2025

Rybrevant Combo Improves Lung Cancer Outcomes After Tagrisso Failure

Ariana Pelosci
Rybrevant plus chemotherapy improved response and delayed disease progression for patients with EGFR-mutated non–small cell lung cancer after Tagrisso.